The Hims & Hers group is going to market a Viagra-type medicine in the form of peppermint lozenges. A discreet drug to meet an increasingly important market
Article written by
Posted
Update
Reading time : 1 min.
The American company Hims & Hers launched in 2017 will market within a few days a new drug to fight against erectile dysfunction. This medication will come in the form of mints. This group is a subscription-based telemedicine site in the United States. The site directs you to the consultation towards a specialist in all discretion. According to the Bloomberg agency, Hims & Hers sometimes put pressure on doctors to prescribe more drugs than necessary. Information disputed by the site.
It is out of this concern for discretion and to circumvent the stigma that the group has therefore created a Viagra-type drug in the form of peppermint lozenges. The white, rectangular box looks like mint-flavored breath lozenges. It’s much more versatile during a romantic date, for example, than those little orange tubes distributed by pharmacies in the United States.
Viagra, a market of 2.3 billion dollars annually
The box is also equipped with a safety preventing children from opening it. The presence of the letters RX also identifies it as a drug. These lozenges will hit the market at the end of February for $30 a month with different strengths available and different ingredients depending on your needs, because it’s not just Sildenafil Citrate, better known as Viagra, on the market.
According to the Grand View Research Institute, this Viagra market represented 2.3 billion dollars worldwide in 2021, with annual growth of more than 8% expected until 2030. If we are to believe the organization world health, 15% of men are affected by erectile dysfunction each year. But as the standard of living also comes into play in the purchase of these drugs, the United States appropriates half of the sales. At 70 dollars per pill on average, Viagra, a product of Pfizer laboratories, remains more sold than Levitra, Cialis or Stendra, which rely on other ingredients. The proliferation of generic versions, which are less expensive, has also made it possible to somewhat broaden access to these treatments.
View comments